Gilead, Jounce Therapeutics sign $805m worth licensing deal for JTX-1811

This article was originally published here

JTX-1811, which is a monoclonal antibody, is said to have been designed by Jounce Therapeutics to preferentially deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. The immunotherapy candidate’s target

The post Gilead, Jounce Therapeutics sign $805m worth licensing deal for JTX-1811 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply